Advertisement

Insulin and New Insulin Analogues, Insulin Pumps and Inhaled Insulin in Type 1 Diabetes

  • Kjeld Hermansen

Keywords: Insulin, insulin analogues, basal bolus insulin treatment, continuous subcutaneous insulin infusion, insulin pump, inhaled insulin, type 1 diabetes mellitus.

Keywords

Glycaemic Control Insulin Glargine Basal Insulin Insulin Analogue Insulin Aspart 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676–1685.CrossRefPubMedGoogle Scholar
  2. 2.
    The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.CrossRefGoogle Scholar
  3. 3.
    The writing group for the Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Research Group. JAMA 2002;287:2563–2569.Google Scholar
  4. 4.
    Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984;7:188–199.CrossRefPubMedGoogle Scholar
  5. 5.
    Brunner GA, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Balent B, Schaupp L, Krejs GJ, Pieber TR. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus. Diabet Med 2000;17(5):371–375.CrossRefPubMedGoogle Scholar
  6. 6.
    Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006;(2):CD003287. DOI:10.1002/14651858. CD003287.pub4.Google Scholar
  7. 7.
    Hagedorn HC, Jensen BN, Krarup NB, Wodstrup I. Protamine insulinate. JAMA 1936;106:177–180.Google Scholar
  8. 8.
    Plank J, Bodenlenz M, Sinner F, Magnes C, Gorzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR. A double-blind, randomized, dose–response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005;28(5):1107–1112.CrossRefPubMedGoogle Scholar
  9. 9.
    Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49(12):2142–2148.CrossRefPubMedGoogle Scholar
  10. 10.
    Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53(6):1614–1620.CrossRefPubMedGoogle Scholar
  11. 11.
    Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151–1167.CrossRefPubMedGoogle Scholar
  12. 12.
    Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007;9(3):290–299.CrossRefPubMedGoogle Scholar
  13. 13.
    Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 2006;23(8):879–886.CrossRefPubMedGoogle Scholar
  14. 14.
    Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med 2006;23(3):285–292.CrossRefPubMedGoogle Scholar
  15. 15.
    Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB. Intensive replacement of basal insulin in patients with Type 1 diabetes given rapid-acting insulin analog at mealtime. Diabetes Care 2003;26:1490–1496.CrossRefPubMedGoogle Scholar
  16. 16.
    Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycaemia with insulin glargine in intensive insulin therapy for Type 1 diabetes. Diabetes Care 2000;23:639–643.CrossRefPubMedGoogle Scholar
  17. 17.
    Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with Type 1 diabetes. Diabetes Care 2000;23:157–162.CrossRefPubMedGoogle Scholar
  18. 18.
    Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with Type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000;23:1137–1142.CrossRefPubMedGoogle Scholar
  19. 19.
    Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin. Diabetes Care 2001;24:296–301.CrossRefPubMedGoogle Scholar
  20. 20.
    Vague P, Selam, J-L, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590–596.CrossRefPubMedGoogle Scholar
  21. 21.
    Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular insulin) in a basal bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622–629.CrossRefPubMedGoogle Scholar
  22. 22.
    De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005;7(1):73–82.CrossRefPubMedGoogle Scholar
  23. 23.
    Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E. Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27(5):1081–1087.CrossRefPubMedGoogle Scholar
  24. 24.
    Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22(7):850–857.CrossRefPubMedGoogle Scholar
  25. 25.
    Russell-Jones D, Draeger E, Esimpson R, Bolinder J, Hylleberg B. Effects of once daily Insulin Detemir or NPH insulin on blood glucose control in people using a basal bolus regimen. Clin Ther 2004;26:724–736.CrossRefPubMedGoogle Scholar
  26. 26.
    Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 2007;9(3):209–217.CrossRefPubMedGoogle Scholar
  27. 27.
    Daneman D. Type 1 diabetes. Lancet 2006;367: 847–858.CrossRefPubMedGoogle Scholar
  28. 28.
    ADA. Standards of medical care in diabetes–2006. Diabetes Care 2006;29(Suppl 1):S4–S42.Google Scholar
  29. 29.
    Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:705–708.CrossRefPubMedGoogle Scholar
  30. 30.
    Benchell-Weissberg J, Antisdel-Lomaglio J, Sehadri R. Insulin pump therapy. Diabetes Care 2003;26:1079–1087.CrossRefGoogle Scholar
  31. 31.
    Siebenhofer A, Plank J, Berghold A, Horvath K, Sawicki PT, Beck P, Pieber TR. Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy. Diabetologia 2004;47(11):1895–1905.CrossRefPubMedGoogle Scholar
  32. 32.
    Hermansen K, Bendtson I, Borch-Johnsen K, Christiansen JS, Henriksen JE, Lervang HH, Nørgaard K. Insulin pump treatment in Denmark (in Danish). Ugeskr Laeger 2004;166(42):3685–3689.PubMedGoogle Scholar
  33. 33.
    National Institute for Clinical Excellence. Technology Appraisal Guidance No 57. Guidance on the use of continuous subcutaneous insulin infusion for diabetes. February 2003 (http://www.NICE.org.UK).
  34. 34.
    Hermansen K. Waiting to inhale: non-injectable insulin, are we there yet? Curr Diab Rep 2004;4(5):335–341.CrossRefPubMedGoogle Scholar
  35. 35.
    Muchmore DB, Gates JR. Inhaled insulin delivery – where are we now? Diabetes Obes Metab 2006;8:634–642.CrossRefPubMedGoogle Scholar
  36. 36.
    Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Int Med 2006;145:665–675.PubMedGoogle Scholar
  37. 37.
    National Institute for Clinical Excellence. Inhaled insulin for the treatment of diabetes (types 1 and 2). NICE technology appraisal guidance 113 (2006). Available from http://www.nice.org.uk/TA113.

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Kjeld Hermansen
    • 1
  1. 1.Department of Endocrinology and MetabolismAarhus University HospitalDenmark

Personalised recommendations